CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) represents the most common inherited small vessel disease of the brain, caused by mutations in the NOTCH3 gene that primarily affect vascular smooth muscle cells (VSMCs), pericytes, and endothelial cells. These mural cells of the cerebral vasculature undergo characteristic pathological changes that lead to progressive small vessel disease, white matter ischemia, and vascular dementia.
| Taxonomy |
ID |
Name / Label |
| Allen Brain Cell Atlas |
Search |
CADASIL Vascular Cells |
| Cell Ontology (CL) |
Search |
Check classification |
| Human Cell Atlas |
Search |
Check expression data |
| CellxGene Census |
Search |
Check cell census |
Vascular smooth muscle cells (VSMCs) form the middle layer (tunica media) of penetrating arterioles and leptomeningeal arteries. In CADASIL, VSMCs undergo profound degenerative changes including:
- Cytoplasmic vacuolization: Formation of numerous cytoplasmic vacuoles that displace normal contractile apparatus
- Basement membrane thickening: Redundant basement membrane layers surrounding VSMCs
- Loss of contractile proteins: Decreased expression of alpha-smooth muscle actin (α-SMA) and smooth muscle myosin heavy chain
- Apoptotic cell death: Increased VSMC apoptosis in affected vessels
These changes impair cerebral autoregulation, the mechanism by which cerebral blood flow is maintained constant across wide ranges of systemic blood pressure.
Pericytes are perivascular cells that wrap around capillary endothelial cells and play critical roles in:
- Blood-brain barrier (BBB) maintenance: Pericyte coverage is essential for BBB integrity
- Capillary stability: Pericytes provide structural support to the capillary wall
- Regulation of capillary diameter: Pericytes can contract and dilate capillaries
- Endothelial proliferation control: Pericytes regulate endothelial cell proliferation
In CADASIL, pericytes show reduced coverage and morphological abnormalities that contribute to BBB dysfunction and microhemorrhages.
While NOTCH3 mutations are not primarily expressed in endothelial cells, secondary endothelial dysfunction occurs in CADASIL due to:
- Impaired communication with degenerating VSMCs
- Reduced production of vasodilatory factors (NO, prostacyclin)
- Increased endothelial activation and adhesion molecule expression
- Altered response to shear stress
NOTCH3 is a single-pass transmembrane receptor expressed primarily in vascular smooth muscle cells and pericytes. It consists of:
- Extracellular domain (ECD): Contains 34 epidermal growth factor-like (EGF) repeats with cysteine residues
- Transmembrane domain: Anchors the receptor in the cell membrane
- Intracellular domain (ICD): Contains the transcriptional activation domain
Over 200 NOTCH3 mutations have been identified in CADASIL patients, nearly all resulting in an odd number of cysteine residues in the EGF-like repeats. This disrupts disulfide bond formation and leads to:
- Misfolding of the extracellular domain: Abnormal protein accumulation
- Impaired receptor trafficking: Reduced surface expression
- Dominant-negative effects: Mutant receptors may interfere with wild-type function
- Gain of toxic function: Abnormal NOTCH3 aggregation
The hallmark pathological feature of CADASIL is GOM deposits composed of:
- Accumulated NOTCH3 extracellular domain fragments
- Extracellular matrix proteins (laminin, collagen IV)
- Vitronectin and other plasma proteins
GOM deposits are found in the basement membranes of VSMCs and pericytes, predating clinical symptoms by decades.
CADASIL shares features with other small vessel diseases:
- Binswanger's disease (subcortical vascular dementia): White matter lesions, lacunar infarcts
- Cerebral amyloid angiopathy (CAA): Small vessel degeneration, microhemorrhages
- Diabetic microangiopathy: basement membrane thickening, pericyte loss
Recent research suggests NOTCH3 signaling may be relevant to Alzheimer's disease:
- NOTCH3 expression increases in AD brains
- NOTCH3 may interact with amyloid-beta processing
- Genetic variants near NOTCH3 may modify AD risk
- VSMC degeneration in AD shares features with CADASIL
¶ Pericytes and Neurodegeneration
Pericyte loss is a shared feature across multiple conditions:
- Alzheimer's disease: Pericyte coverage reduced by 30-50% in AD brains
- Parkinson's disease: Nigral pericyte dysfunction may contribute to neurodegeneration
- Amyotrophic lateral sclerosis: Pericyte-endothelial barrier disruption
- Multiple sclerosis: Pericyte loss in active lesions
BBB breakdown is increasingly recognized in neurodegeneration:
- Aβ clearance failure: Pericytes and endothelial cells mediate Aβ efflux
- Inflammatory cell infiltration: BBB leakage allows peripheral immune cell entry
- Trojan hypothesis: Peripheral proteins may enter through compromised BBB
- Vascular hypothesis of AD: Cerebrovascular dysfunction as upstream event
MRI findings in CADASIL include:
- White matter hyperintensities: Confluent lesions in periventricular and deep white matter
- Lacunar infarcts: Small subcortical infarcts in basal ganglia, thalamus, pons
- Cerebral microbleeds: Small hemorrhages detected on T2* GRE or SWI
- Brain atrophy: Particularly in the frontal lobes and corpus callosum
The cellular changes in CADASIL correlate with imaging findings:
- VSMC degeneration → Reduced vascular reactivity → White matter ischemia
- Pericyte loss → BBB breakdown → White matter hyperintensities
- GOM deposition → Vessel wall thickening → Lacunar infarcts
No disease-modifying therapy exists for CADASIL. Current approaches include:
- Blood pressure control: Maintaining adequate cerebral perfusion
- Antiplatelet therapy: Controversial due to hemorrhage risk
- Statins: May improve endothelial function
- Avoidance of anticoagulants: High hemorrhage risk
Several approaches are under investigation:
- NOTCH3 aggregation inhibitors: Small molecules targeting abnormal aggregation
- BBB stabilization: Agents promoting pericyte function
- Gene therapy: Viral vector-mediated wild-type NOTCH3 delivery
- Stem cell therapy: Replacing degenerated VSMCs and pericytes
Given the central role of pericytes:
- PDGF-BB analogs: Promote pericyte recruitment and survival
- S1P receptor modulators: Enhance pericyte coverage
- TGF-β pathway modulators: Support pericyte differentiation
- Aβ-neutralizing agents: Reduce pericyte toxicity from Aβ deposition
- Patient-derived VSMCs: iPSC differentiation to study mutation effects
- NOTCH3-transfected cell lines: Overexpression of mutant vs wild-type
- 3D vessel organoids: Vascular networks with pericytes and endothelial cells
- NOTCH3 transgenic mice: Express human mutant NOTCH3
- NOTCH3 knockout mice: Developmental and adult deletion
- BBB permeability assays: Tracer extravasation studies
- NOTCH3 ectodomain: Detectable in plasma and CSF
- GOM proteins: Antibodies against GOM components
- Endothelial markers: VWF, E-selectin, VCAM-1
- Pericyte markers: PDGFRβ, CD13, NG2
CADASIL provides a unique window into the role of vascular mural cells in neurodegeneration. The study of VSMCs, pericytes, and endothelial cells in this monogenic condition reveals mechanisms relevant to sporadic small vessel disease and broader neurodegenerative processes. Understanding pericyte-VSMC-endothelial interactions may lead to novel therapeutic approaches for both rare and common forms of vascular cognitive impairment.